Patient-friendly, non-technical summary of research papers

February 2026 Research Update

This report covers research on Mucopolysaccharidosis type III (Sanfilippo syndrome) published in PubMed in February 2026. For other months, see all research updates.

Last update: May 19, 2026

At a glance

Confirming the subtype

Broad genetic testing did not detect every kind of gene change, and enzyme testing plus targeted genetic follow-up helped confirm Sanfilippo type IIIB in one family.

Very early trehalose results

In two siblings, six trehalose injections were reported with no measurable improvement, which is a limited observation rather than clear evidence of benefit.

Acute metabolic acidosis case

One person with Sanfilippo type A was reported with an episode of acute metabolic acidosis, but a single case cannot show how common or predictable this is.

What these reports add

This month mainly added examples of missed genetic findings and uncommon presentations, which helps describe testing limits and person-to-person variation without adding broadly applicable treatment evidence.

Overview

This month shifted toward diagnosis details rather than treatment progress, with case reports showing that broad genetic tests can miss important Sanfilippo gene changes and that follow-up testing sometimes changes the final answer.

A consistent pattern across the reports was that confirming a specific Sanfilippo subtype can take more than one kind of test. In one family with two siblings who had mucopolysaccharidosis type IIIB, enzyme testing showed absent NAGLU activity, and later genetic work found two disease-causing NAGLU changes. One of those was a duplication that whole-exome sequencing did not capture at first, which helps explain how an early genetic result can look incomplete or uncertain.

Treatment-related information was present, but it stayed narrow and hard to generalize. The same two siblings tried trehalose, and the report described no measurable clinical improvement after six injections. In a separate single-person report in Sanfilippo type A, an episode of acute metabolic acidosis was described along with a specific SGSH gene change (c.571G>A) noted as the first documented instance of that mutation.

The main open question is how often these diagnostic gaps and rare presentations happen across the broader Sanfilippo community.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Sanfilippo syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month added two case reports that mainly expand the catalog of how Sanfilippo syndromes can present and how genetic testing can confirm the exact subtype. One report showed how a diagnosis can be missed or delayed when standard genetic testing does not fully capture certain variant types, and how follow-up targeted testing can clarify the result. The other report described an unusual acute illness at presentation in a person with Sanfilippo type A and documented a previously unreported genetic change in that gene.

In a family with two siblings with MPS IIIB, enzyme testing showed absent NAGLU activity and sequencing ultimately confirmed two NAGLU variants causing compound heterozygous disease, after whole-exome sequencing first flagged only one uncertain variant and missed the duplication. The report also noted brain imaging changes and other supportive clinical findings, which together matched MPS IIIB. This helps illustrate that combining enzyme testing with the right kind of genetic test can be important when the first genetic result is incomplete or uncertain.

A separate single-patient report in Sanfilippo type A described an episode of acute metabolic acidosis and identified a homozygous SGSH c.571G>A change, described as the first documented instance of that specific mutation. The 13-year-old had a long history of developmental regression and behavioral change and was unconscious during the acute episode; she regained consciousness after the acidosis was corrected and supportive care was given. Genetic testing together with markedly reduced enzyme activity confirmed the diagnosis. Because it is one patient, it cannot show how often this kind of acute event happens in Sanfilippo or whether it is linked to that mutation. Its main contribution is documenting a rare presentation and adding one more data point to the list of known SGSH gene changes.

One report also included an early treatment attempt: the two siblings with MPS IIIB started a trehalose trial, and the authors reported no measurable clinical improvement by six injections. With only two patients and a short follow-up, this does not answer whether trehalose could help some people, but it does show that in this particular family there was no early observable change over that brief period.

For patients and caregivers, this month mostly adds understanding rather than changing what is known about care. The reports highlight that confirming the exact Sanfilippo subtype may require both enzyme testing and genetic testing that can detect different kinds of gene changes, especially if an initial test result is uncertain. They also show that unusual acute illnesses can occur in an individual patient, but a single case cannot tell whether that event is common or predictable. The trehalose experience is early and very limited, so its meaning is mainly as a research observation rather than a clear signal of benefit.

Limitations

Evidence came from two case reports, so findings cannot estimate how common they are.
The trehalose experience involved only two siblings and short follow-up after six injections.
The acute metabolic acidosis event was reported in a single person, so links to genetics remain uncertain.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.